Literature DB >> 8172890

Active-site mutations of the diphtheria toxin catalytic domain: role of histidine-21 in nicotinamide adenine dinucleotide binding and ADP-ribosylation of elongation factor 2.

S R Blanke1, K Huang, B A Wilson, E Papini, A Covacci, R J Collier.   

Abstract

Diphtheria toxin (DT) has been studied as a model for understanding active-site structure and function in the ADP-ribosyltransferases. Earlier evidence suggested that histidine-21 of DT is important for the ADP-ribosylation of eukaryotic elongation factor 2 (EF-2). We have generated substitutions of this residue by cassette mutagenesis of a synthetic gene encoding the catalytic A fragment (DTA) of DT, and have characterized purified mutant forms of this domain. Changing histidine-21 to alanine, aspartic acid, leucine, glutamine, or arginine diminished ADP-ribosylation activity by 70-fold or greater. In contrast, asparagine proved to be a functionally conservative substitution, which reduced ADP-ribosylation activity by < 3-fold. The asparagine mutant was approximately 50-fold-attenuated in NAD glycohydrolase activity, however. Dissociation constants (Kd) for NAD binding, determined by quenching of the intrinsic protein fluorescence, were 15 microM for wild-type DTA, 160 microM for the asparagine mutant, and greater than 500 microM NAD for the alanine, leucine, glutamine, and arginine mutants. These and previous results support a model of the ADP-ribosylation of EF-2 in which histidine-21 serves primarily a hydrogen-bonding function. We propose that the pi-imidazole nitrogen of His-21 hydrogen-bonds to the nicotinamide carboxamide, orienting the N-glycosidic bond of NAD for attack by the incoming nucleophile in a direct displacement mechanism, and then stabilizing the transition-state intermediate of this reaction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172890     DOI: 10.1021/bi00183a019

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Design of highly specific cytotoxins by using trans-splicing ribozymes.

Authors:  B G Ayre; U Köhler; H M Goodman; J Haseloff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Crystal structure of human ADP-ribose transferase ARTD15/PARP16 reveals a novel putative regulatory domain.

Authors:  Tobias Karlberg; Ann-Gerd Thorsell; Åsa Kallas; Herwig Schüler
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

3.  Structural basis for lack of ADP-ribosyltransferase activity in poly(ADP-ribose) polymerase-13/zinc finger antiviral protein.

Authors:  Tobias Karlberg; Mirjam Klepsch; Ann-Gerd Thorsell; C David Andersson; Anna Linusson; Herwig Schüler
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

4.  Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen.

Authors:  S R Blanke; J C Milne; E L Benson; R J Collier
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

5.  Halovibrin, secreted from the light organ symbiont Vibrio fischeri, is a member of a new class of ADP-ribosyltransferases.

Authors:  K A Reich; G K Schoolnik
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

6.  The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: conformational differences with the intact exotoxin.

Authors:  M Li; F Dyda; I Benhar; I Pastan; D R Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 12.779

7.  Ligand Selectivity between the ADP-Ribosylating Toxins: An Inverse-Docking Study for Multitarget Drug Discovery.

Authors:  Patricia Saenz-Méndez; Martin Eriksson; Leif A Eriksson
Journal:  ACS Omega       Date:  2017-04-28

8.  A novel predicted ADP-ribosyltransferase-like family conserved in eukaryotic evolution.

Authors:  Zbigniew Wyżewski; Marcin Gradowski; Marianna Krysińska; Małgorzata Dudkiewicz; Krzysztof Pawłowski
Journal:  PeerJ       Date:  2021-03-10       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.